BioWorld

Nov. 3, 2008

Biogen Idec Joins Genentech, Roche on Anti-CD20 Antibody

Biogen Idec Inc. said it will pay a $31.5 million up-front fee to join Genentech Inc. and F. Hoffmann-La Roche Ltd. in the development of a humanized anti-CD20 monoclonal antibody, GA101. (BioWorld Today) Read More

Polyphor Would Get $7M Boost in Eye Drug Deal with Allergan

How Biotech Can Make Even Cash Look Bad

Panel: Focus on Long Term to Weather Economic Storm

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...